997 related articles for article (PubMed ID: 29452209)
1. Prolactin improves hepatic steatosis via CD36 pathway.
Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
[TBL] [Abstract][Full Text] [Related]
2. Ablation of prolactin receptor increases hepatic triglyceride accumulation.
Shao S; Yao Z; Lu J; Song Y; He Z; Yu C; Zhou X; Zhao L; Zhao J; Gao L
Biochem Biophys Res Commun; 2018 Apr; 498(3):693-699. PubMed ID: 29524401
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
4. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
[TBL] [Abstract][Full Text] [Related]
5. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
[TBL] [Abstract][Full Text] [Related]
6. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.
Heebøll S; Poulsen MK; Ornstrup MJ; Kjær TN; Pedersen SB; Nielsen S; Grønbæk H; Handberg A
Int J Obes (Lond); 2017 Feb; 41(2):262-267. PubMed ID: 27916988
[TBL] [Abstract][Full Text] [Related]
7. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-26a-CD36 signaling pathway: Pivotal role in lipid accumulation in hepatocytes induced by PM
Ding D; Ye G; Lin Y; Lu Y; Zhang H; Zhang X; Hong Z; Huang Q; Chi Y; Chen J; Dong S
Environ Pollut; 2019 May; 248():269-278. PubMed ID: 30798028
[TBL] [Abstract][Full Text] [Related]
9. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
10. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
[TBL] [Abstract][Full Text] [Related]
12. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada P; González-Rodríguez Á; García-Monzón C; Valverde ÁM
Cell Death Dis; 2020 Sep; 11(9):802. PubMed ID: 32978374
[TBL] [Abstract][Full Text] [Related]
13. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
[TBL] [Abstract][Full Text] [Related]
14. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.
Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W
J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452
[TBL] [Abstract][Full Text] [Related]
15. Dietary sucrose regulates the expression of the Cd36 gene in hepatic tissue of rats with obesity and Non Alcoholic Fatty Liver Disease (NAFLD).
Castro RQ; Soto Rodriguez I; Deschamps Lago RA; Pagola PG; Rodriguez Antolin J; Peres Quintal A; Rivera JR; Aguilera AA
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Jun; 162(2):99-106. PubMed ID: 29765172
[TBL] [Abstract][Full Text] [Related]
16. Prolactin (PRL) receptor gene expression in mouse adipose tissue: increases during lactation and in PRL-transgenic mice.
Ling C; Hellgren G; Gebre-Medhin M; Dillner K; Wennbo H; Carlsson B; Billig H
Endocrinology; 2000 Oct; 141(10):3564-72. PubMed ID: 11014209
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
[TBL] [Abstract][Full Text] [Related]
18. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
Lee MR; Yang HJ; Park KI; Ma JY
Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
[TBL] [Abstract][Full Text] [Related]
19. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
[TBL] [Abstract][Full Text] [Related]
20. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
Xiao Z; Chu Y; Qin W
Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
